Last reviewed · How we verify
CYB704
CYB704 is a selective inhibitor of complement factor D that reduces complement cascade activation and downstream inflammatory responses.
CYB704 is a selective inhibitor of complement factor D that reduces complement cascade activation and downstream inflammatory responses. Used for Age-related macular degeneration (AMD).
At a glance
| Generic name | CYB704 |
|---|---|
| Also known as | Ocrelizumab |
| Sponsor | Sandoz |
| Drug class | Complement Factor D inhibitor |
| Target | Complement Factor D |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Factor D is a serine protease essential for initiating the alternative complement pathway. By inhibiting Factor D, CYB704 suppresses complement-mediated inflammation and tissue damage. This mechanism is being explored in complement-driven inflammatory and degenerative diseases.
Approved indications
- Age-related macular degeneration (AMD)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYB704 CI brief — competitive landscape report
- CYB704 updates RSS · CI watch RSS
- Sandoz portfolio CI